Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor

• DOI: 10.4174/astr.2019.97.5.223
• Publication Date: 2019-11-08T08:37:20Z
• Authors: Je Hyung Park; Hyun Yul Kim; Youn Joo Jung; Dong Il Kim; Jee Yeon Kim; Hyun-June Paik
• Keywords: Concordance

Core needle biopsy (CNB) is a widely used procedure for breast cancer diagnosis and analyzing results of immunohistochemistry (IHC). Several studies have shown concordance or discordance in IHC between CNB surgical specimens (SS). A double-check (CNB SS) inefficient costly to perform on all patients. Therefore, it important determine which patients would benefit from double-check.We collected the medical records who underwent surgery at Pusan National University Yangsan Hospital April 2009 June 2018 (n = 620). Molecular subtypes were classified as follows by hormone receptors (HR) human epidermal growth factor receptor-2 (HER2): HR+/HER2+, HR+/HER2-, HR-/HER2+, HR-/HER2-. Clinicopathological factors including age, obesity, histological grade, preoperative CEA, CA15-3, T stage, N menopausal status assessed whether they associated with subtype change.Increasing grade (P < 0.001; odds ratio [OR], 3.693; 95% confidence interval [CI], 1.941-7.025), CEA ≥ 5 ng/mL =0.042; OR, 2.399; CI, 1.009-5.707) higher stage 0.015; 2.241; 1.152-4.357) significantly change. On multivariable analyses, changes more common high-grade 1.077; 1.031-1.113) 0.032; 2.658; 1.088-6.490).Patients moderate- tumors are required molecular cancer.